The First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial to Assess the Antitumor Activity and Tolerability of the Probody™ Therapeutic CX-072 as Monotherapy and in Combination With Ipilimumab or Vemurafenib in Solid Advanced Tumors and Lymphomas

Valentina Boni, Javier Garcia-Corbacho, Jaime Feliu, Jerzy Wydmanski, Zsolt Horvath, Igor Bondarenko, Bryan Irving, Matthias Will, Elisabeth de Vries, Fiona Thistlethwaite. Poster presented at ESMO 2017, September 8-12, Madrid, Spain.